Equity Profile

OGN

Organon & Co.

Health CarePharmaceuticals$3.6B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Organon & Co. is a pharmaceutical company focused on women's health and other critical health needs....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$1.07

Revenue

Total revenue gives insight into the company's sales performance and market demand for its products.

$1.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

OGN Q2-2026 Earnings Preview

Context

Company Snapshot

Organon & Co. is a pharmaceutical company focused on women's health and other critical health needs. Operating in the health care sector, it plays a significant role in developing medicines that address various health issues, making it important for both patients and investors.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+7.95%

Avg Stock Reaction

-3.38%

Last Quarter Recap

In Q1 2026, Organon reported an EPS of $0.71, which was below the expected $0.81, resulting in a 12.88% negative surprise. The stock reacted with a slight decline of 0.67% the following day.

Management Promises & Guidance

Focus on improving product pipeline and addressing market needs.
Commitment to enhancing operational efficiency.
Plans to expand into new markets.

Expectations

Wall Street Expectations

Analysts expect Organon to report earnings that meet the consensus estimates, reflecting a cautious optimism in the market.

Bull Case

If the company exceeds EPS and revenue expectations, it could signal strong demand for its products and effective management strategies.

Bear Case

A miss on earnings or revenue could raise concerns about the company's growth prospects and market competitiveness.

Key Metrics to Watch

EPS

$1.07

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$1.6B

Total revenue gives insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.07?

A beat on EPS could indicate stronger profitability and investor confidence, impacting stock performance.

What are the revenue figures compared to the expected $1.6B?

Revenue performance will be crucial in assessing market demand and the effectiveness of the company's strategies.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth driven by new product launches and market expansion.

Supporting Evidence

Recent trends in women's health indicate increasing demand for Organon's products.

The company's historical ability to outperform estimates suggests it may do so again.

Options pricing indicates a significant expected move, reflecting uncertainty that could lead to a surprise.

Key Risk

If revenue significantly exceeds $1.6B, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to deliver on earnings and revenue expectations amidst recent performance trends.

Bull Confirmed If

An EPS above $1.07 and revenue exceeding $1.6B would confirm the bull case.

Bear Confirmed If

An EPS below $1.07 and revenue below $1.5B would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.36%

Historical Avg

±10.8%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty around the earnings report.

Options are pricing ±21.4% while OGN has averaged ±10.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

95.4%

Calls (3K)P/C Ratio: 0.53Puts (52K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Organon beats expectations, history suggests a potential average move of +3.1%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of -4.43% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on new product launches and their expected impact on revenue.
2Any updates on market expansion efforts and their timelines.
3Insights into cost management strategies and operational efficiencies.
4Management's outlook on competitive pressures in the pharmaceutical sector.
5Guidance on future earnings expectations and growth strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Organon & Co. is a pharmaceutical company focused on women's health and other critical health needs....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$1.07

Revenue

Total revenue gives insight into the company's sales performance and market demand for its products.

$1.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

OGN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+7.95%

Avg Stock Reaction

-3.38%

Last Quarter Recap

In Q1 2026, Organon reported an EPS of $0.71, which was below the expected $0.81, resulting in a 12.88% negative surprise. The stock reacted with a slight decline of 0.67% the following day.

Management Promises & Guidance

Focus on improving product pipeline and addressing market needs.
Commitment to enhancing operational efficiency.
Plans to expand into new markets.

Expectations

Wall Street Expectations

Analysts expect Organon to report earnings that meet the consensus estimates, reflecting a cautious optimism in the market.

Bull Case

If the company exceeds EPS and revenue expectations, it could signal strong demand for its products and effective management strategies.

Bear Case

A miss on earnings or revenue could raise concerns about the company's growth prospects and market competitiveness.

Key Metrics to Watch

EPS

$1.07

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$1.6B

Total revenue gives insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.07?

A beat on EPS could indicate stronger profitability and investor confidence, impacting stock performance.

What are the revenue figures compared to the expected $1.6B?

Revenue performance will be crucial in assessing market demand and the effectiveness of the company's strategies.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth driven by new product launches and market expansion.

Supporting Evidence

Recent trends in women's health indicate increasing demand for Organon's products.

The company's historical ability to outperform estimates suggests it may do so again.

Options pricing indicates a significant expected move, reflecting uncertainty that could lead to a surprise.

Key Risk

If revenue significantly exceeds $1.6B, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to deliver on earnings and revenue expectations amidst recent performance trends.

Bull Confirmed If

An EPS above $1.07 and revenue exceeding $1.6B would confirm the bull case.

Bear Confirmed If

An EPS below $1.07 and revenue below $1.5B would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.36%

Historical Avg

±10.8%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty around the earnings report.

Options are pricing ±21.4% while OGN has averaged ±10.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

95.4%

Calls (3K)P/C Ratio: 0.53Puts (52K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Organon beats expectations, history suggests a potential average move of +3.1%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of -4.43% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on new product launches and their expected impact on revenue.
2Any updates on market expansion efforts and their timelines.
3Insights into cost management strategies and operational efficiencies.
4Management's outlook on competitive pressures in the pharmaceutical sector.
5Guidance on future earnings expectations and growth strategies.